
EBITDA Multiple Explained (How to Value Your Business)
The video breaks down the EBITDA multiple, the metric buyers use to price a company based on its annual operating profit. It explains why EBITDA—earnings before interest, taxes, depreciation, and amortization—offers a cleaner, apples‑to‑apples view of cash generation than net income. Key points include the simple formula (EBITDA × multiple = enterprise value), typical ranges (four to eight times for lower‑middle‑market firms), and the distinction between trailing EBITDA (auditable past 12 months) and forward EBITDA (projected). Industry dynamics matter: software and SaaS command 6‑15×, marketing agencies 4‑7×, professional services 3‑6×, while capital‑intensive manufacturers sit lower due to reinvestment needs. The presenter cites a $3 million‑revenue marketing agency earning $600 k EBITDA sold for $3.6 million (a six‑times multiple) and warns against over‑reliance on optimistic forward numbers. He stresses that client concentration above 15 % and founder dependence erode multiples, and that recurring revenue, diversified client bases, and low capex can add premium points. For business owners, the takeaway is clear: clean up financials, document systems, and build recurring, low‑risk revenue streams before entering a sale process. Doing so can shift a valuation from four to seven times EBITDA, translating into millions of dollars in exit proceeds.

Where Your Fund Fits in an LP Portfolio (And Why Specialization Isn’t for Everyone)
The discussion centers on how limited partners (LPs) should evaluate where a fund sits within their broader investment portfolio, weighing the appeal of sector‑specialized managers against the need for diversification. It highlights a market bias toward niche strategies while warning...

MD&M 2026 Keynote: $6.1B Advice From Ray Cohen and Tom West!
The MD&M West 2026 keynote, titled “Disrupting the Status Quo: Are We Innovating or Just Iterating?”, brought together veteran deal‑maker Ray Cohen and former J&J executive Tom West to debate what true innovation looks like in medical technology. Cohen warned that...

Cellbricks Secures $10M
Berlin‑based Celicks announced a $10 million financing round aimed at accelerating its proprietary 3D bioprinting platform for vascularized tissue implants. The capital will fund the transition of its lead programs from pre‑clinical studies into early‑stage clinical trials, positioning the startup at...

Are Orbital Data Centers All Hype, or an Actual AI Infrastructure Solution? L Equity Podcast
The Equity Techrunch podcast opened with a quick recap of Disney’s Olaf robot mishap before turning to the week’s biggest financing news: OpenAI’s $122 billion private round that pushes its post‑money valuation to $852 billion, and Whoop’s $575 million raise at a $10.1 billion...

Squawk Pod: World Autism Awareness Day - 04/03/26 | Audio Only
On World Autism Awareness Day, CNBC’s Squawk Pod featured Christopher Male, co‑founder of the Autism Impact Fund (AIF), announcing the first close of its second fund. The new vehicle expands AIF’s mandate beyond traditional behavioral‑health services to encompass broader behavioral, mental‑health...

OpenAIs 122bn Funding Round!?
The episode spotlights three headline‑making developments: OpenAI’s $122 billion financing that lifts its valuation to $852 billion, Anthropic’s new AI‑safety agreement in Australia, and a federal judge’s green light for a class‑action lawsuit against Elon Musk over his delayed Twitter‑stock disclosure. OpenAI’s capital...

Why Female Founders Are Still Overlooked - Interview with Ropa Popat, Founder of Arāya Ventures
Rupa Popat, founder and managing partner of Arete Ventures, discusses how her London‑based firm blends a strong AI investment thesis with a mission to back diverse, especially female‑led, founders. Launched in 2022, Arete backs early‑stage companies across health‑tech, future‑of‑work, commerce...

Rivian Electric Bike Spinoff Signs Deal with DoorDash
Rivian’s recently spun‑out electric‑bike unit announced a partnership with DoorDash to deploy its TMB e‑bike platform for last‑mile delivery. The collaboration marks the first major commercial rollout of the company’s vertically integrated, software‑defined EV solution for small‑form‑factor logistics. The TMB starts...

Investing at Inception in the Age of AI Agents | Ed Sim (Founder & GP, Boldstart)
The conversation with Ed Sim, founder and GP at Boldstart, centers on how investors and senior operators must rethink decision‑making in the age of AI agents. Sim frames career moves as venture‑capital bets, urging executives to treat their time like...

How Does Net Revenue Retention Impact Your Valuation? | SaaS Metrics School | NRR
Net revenue retention (NRR) is a pivotal metric that directly influences SaaS company valuations, as explained by Ben Murray in the SaaS Metrics School episode. He cites Meritech Capital data showing that firms with 102% NRR command sub‑5x revenue multiples,...

EquipmentShare’s $6B IPO, AI in Construction, and the Future of the Job Site | Willy Schlacks
EquipmentShare, a construction‑technology and equipment‑rental firm, announced its $6 billion‑valued IPO on the Nasdaq, raising $747 million. Co‑founder Willie Schlacks discussed why the public market was the logical next step for a company that has surpassed $1 billion in revenue and is tackling...

Investing In Early-Stage Oncology With Yosemite's Dan McHugh
The Business of Biotech episode spotlights Dan McHugh, head of the investment team at Yosemite, a San Francisco‑based venture firm founded by Reed Jobs and Loren Powell Jobs. Yosemite’s mandate is to fund early‑stage cancer‑therapeutics developers, leveraging a mission‑driven capital pool that grew out of...

Founders & Funders Roadshow Q&A | Startup CPG
The Founders & Funders Roadshow Q&A introduced Startup CPG’s new traveling event series, an extension of the December New York summit. Daniel, the founder, explained that the roadshow brings together early‑stage consumer‑goods brands and a curated pool of active venture...

Crypto Venture: Is There Still Any Alpha? | DAS NYC 2026 | Day 3 | Investor
At DAS New York 2026, a panel of crypto veterans—including Catrina Wang, Soona Amhaz, Mike Dudas, Marcos Veremis, and Richard Muirhead—debated whether venture capital can still generate alpha in the maturing cryptocurrency market. The discussion highlighted a shift from speculative...

Why You Need a $1B Fund To Do Series A | SpaceX at $2TRN & Data Centers in Space |...
The episode dissected the rapidly shifting AI landscape, highlighting Anthropic’s surge to dominate 73% of fresh enterprise AI spend while OpenAI’s once‑unassailable position appears to wobble. The conversation also touched on Jeff Bezos’s trillion‑dollar ambitions for SpaceX, Groq’s massive $20 billion...

450: World Agri-Tech Takeaways + AgFunder Investment Report
The episode recaps Tim and Ty’s experience at the World AgriTech Innovation Summit in San Francisco, tying it to the latest AgFunder investment report. They note that while overall attendance was lighter than previous years, the concentration of high‑quality decision‑makers...

We're Adding a New GTMfund Partner. Here's Why It Changes Everything.
The episode announces the appointment of Jason Damont as a partner and head of networks at GTM Fund, marking the first formal staffing of its platform and network function. Damont brings a decade‑long track record at Foundation Capital, where he...

Peptides Target “Undruggable” Diseases
Santa Cruz‑based company specializing in unnatural macrocyclic peptide therapeutics announced a $45 million Series B round and a $1.7 billion collaboration with Novartis. The partnership targets cardiovascular proteins that have eluded conventional small‑molecule and antibody approaches. The firm positions macrocyclic peptides between traditional small...

Inside The Startup Reinventing America’s Trillion Dollar Chemical Industry
The video profiles Solugen, a Houston‑based startup that is redefining the trillion‑dollar U.S. chemical industry by fusing biology and traditional catalysis. Its proprietary "chematic processing" pairs enzymes extracted from corn‑derived feedstock with novel metal catalysts, boosting reaction yields from...

Why This VC Wouldn’t Invest in MrBeast
The video features a venture capitalist explaining why his firm would not invest in MrBeast, despite the creator’s massive audience. He emphasizes that the firm’s mandate is to back entrepreneurs who build scalable businesses, not merely entertainers who enjoy making...

38 | The Entrepreneur's Dilemma: When Should You Sell or Raise Capital?
The episode of “Path to Exit” tackles the entrepreneur’s dilemma—when to sell a thriving software business or raise new capital. Host Mike Lion and Vista Point MD Jeff Coons explain why timing a liquidity event matters more than the eventual...

The Investor Behind A16z’s America First Push On Dealing With the Pentagon ‘Where Bits Meet Atoms’
The interview on Compound Interest introduces Andreessen Horowitz’s American Dynamism Fund, a venture‑capital vehicle created to channel private capital into sectors the firm deems essential to the United States’ national and economic security. Partner David Ulovich explains that the fund...

They Call It a Lottery Ticket. The Data Says Otherwise | The Hidden Alpha of Biotech
Biotech investing is portrayed as a lottery ticket, yet specialist investors argue persistent alpha exists. The conversation with DA Wallak explores how early‑stage biotech firms are valued using a “bag of options” framework that sums the net present value of...

Sam Altman's $110B OpenAI Round: The Economy Game Changer #shorts
The video spotlights Sam Altman's latest financing feat—OpenAI secured a private round of roughly $110 billion, a sum that eclipses the biggest initial public offering in history. At a time when the company reports about $2.4 billion in revenue, the capital raise is...

The Problem With Investing in Capital-Hungry Startups
The discussion centers on the inherent difficulty of seed‑stage investing in capital‑intensive startups. Venture partners explain that they typically set aside follow‑on capital equal to the amount initially deployed, recognizing that many high‑profile ventures, such as AI labs, consume massive...

Wiz’s First Investor Breaks Down Google’s $32B Acquisition │ Equity Podcast
The Equity Podcast episode features Wiz’s first investor dissecting Google’s $32 billion purchase of the cloud‑security startup, framing it within broader M&A theory. He argues that acquisitions fall into three size categories—small, medium, large—and that the extremes tend to generate the most...

The $32B Acquisition that One VC Is Calling the 'Deal of the Decade' | Equity Podcast
The Equity Podcast’s latest episode centers on Google’s monumental $32 billion acquisition, which Index Ventures partner Shardul Shaw hails as the "Deal of the Decade." The conversation pivots to broader industry trends, including a whistleblower’s claim that a former Doge employee...

Why Most Seed Funds Are Too Small or Too Big
The video argues that seed‑stage venture capital performs best when the fund sits in the $100‑200 million range, a “sweet spot” that balances capital availability with the ability to take meaningful equity stakes. The speaker explains that larger funds must spread...

Who Actually Takes More Risk? | Nicolai Tangen
The video explores how risk tolerance varies across demographics and investment domains, questioning whether men, younger people, extroverts or Americans truly take more risks than their counterparts. Nicolai Tangen draws on social‑psychology research to illustrate that gender, age, personality traits...

Poppi Founder on TikTok, Super Bowl Ads, and Her Return to Shark Tank | Equity Podcast
The Equity podcast episode features Poppi co‑founder Alison Ellsworth, who recounts how a kitchen‑born prebiotic soda grew into a $1.95 billion PepsiCo acquisition. She details the brand’s launch during the first week of COVID, its digital‑first strategy, and how early Shark Tank...

Venture:How Olympus Innovation Ventures Invests in MedTech Startups with Abby Hunter Syed
Olympus Innovation Ventures (OIV), the corporate venture arm of Olympus, is actively investing in MedTech startups focused on endoscopy, diagnostics, and digital health, as explained by director Abby Hunter‑Syed. The discussion highlights OIV’s strategic approach—prioritizing founder conviction, transparent founder‑investor relationships,...

Why Venture Capitalists Make Millions Even If Funds Fail
The video dissects the paradox that venture‑capital partners routinely earn multi‑million‑dollar incomes even when their funds under‑perform or collapse. It argues that the core of this phenomenon lies in the fee architecture—steady management fees and carried‑interest structures—that decouple personal compensation...

Legal AI Startup Legora Raises $550 Million for US Expansion
Legal AI startup Legora announced a $550 million financing round led by top venture investors, earmarked for aggressive expansion across the United States. CEO Max Junestrand told Bloomberg Tech that the infusion will accelerate product rollout and help the firm scale...

Stay22 Announces $122 Million Growth Capital
Stay22 disclosed a $122 million growth‑capital round, positioning the company for rapid expansion beyond its core travel‑booking map service. CEO Andrew Lockhead outlined the funding’s purpose on BNN Bloomberg, emphasizing product innovation, geographic reach, and entry into adjacent markets such as...

What Convinces An Investor To Back A First Time Founder | João Moura X Data Science Dojo
The video features João Moura discussing what convinces investors to back first‑time AI founders. He frames the current AI boom as a rare, high‑stakes opportunity, but warns that the surge in tools and applications creates fierce competition and an uphill...

"Cursor Is Dead" Is Total BS: Here Is Why | Miles Clements
Miles Clements rejects the narrative that “Cursor is dead,” arguing that the coding-AI market is expanding rather than zero-sum and that cursor remains strong because coding tools combine fast time-to-value with durable productivity gains. He lays out a framework of...

Katelin Holloway – Human Side of Venture Investing at 776 (EP.490)
The episode centers on Katelin Holloway, founding partner of 776, a technology‑focused venture firm she launched with Alexis Ohanian in 2020. Drawing on a decade of HR leadership at Pixar, Clout and Reddit, Holloway argues that early‑stage investing is fundamentally...

Mitchell Green: Why 50% of VCs Should Not Exist & Why China Will Win the AI War
Mitchell Green, a veteran investor behind Alibaba, Bite Dance and Grafana, warned that the venture‑capital ecosystem is saturated, arguing that roughly half of today’s VCs contribute little or even negative value to portfolio companies. He highlighted an imminent market correction,...

Anthropic vs The Pentagon: Who Wins? | Cursor Hits $2BN in ARR | Block's 40% Headcount Reduction
Anthropic and the Pentagon clashed after Anthropic sought contractual limits on use of its models — banning mass surveillance and autonomous weapons — prompting the Defense Department to halt talks and threaten cancellation or wider procurement consequences. The rupture underscores...

How Is Saudi Private Capital Adopting AI: Insights From Jada Fund of Funds Fund Manager Report
The Jada Fund of Funds released a report detailing how Saudi private capital is integrating artificial intelligence into its investment workflows. Backed by visionary leadership and a national AI strategy, the study surveyed over 45 general partners (GPs) and incorporated...

Ep. 117: Scott Neuberger, Karmel Capital | Data-Driven Secondaries in Software and AI
The episode features Scott Neuberger, managing partner of Karmel Capital, discussing the firm’s data‑driven approach to secondary market investing in later‑stage enterprise software and AI infrastructure. He explains how Karmel raises committed capital from institutions and family offices, then deploys...

Lecture 1.1.4B | Healthcare Funding & Startup Failure (Part B) | Masters in Medical Entrepreneurship
The lecture dissects the unique financing trajectory of healthcare startups, emphasizing that capital must flow slower, deeper, and with heightened risk awareness compared with consumer tech. It outlines the funding ladder—from $10K‑$100K pre‑seed idea validation, through $100K‑$2M seed pilots, to...

Gavin Baker – Truth-Seeking and Crossover Investing at Atreides (EP.489)
The Capital Allocators episode spotlights Gavin Baker, managing partner and CIO of Atreides Management, which oversees roughly $7 billion across public, private and crossover strategies focused on technology and consumer sectors. Baker recounts his unconventional path—from a book‑filled childhood and rock‑climbing...

The SaaS Apocalypse: Who Lives & Who Dies | Insight Partners Co-Founder, Jerry Murdock
Jerry Murdock, co‑founder of Insight Partners, warns of a looming SaaS apocalypse driven by autonomous AI agents that act as virtual employees. He outlines how AI orchestration layers, ASIC chips, and Nvidia’s dominance reshape the tech stack, while one‑person AI...

The $100M–$200M Rule for Seed Funds
The video outlines a rule of thumb for seed‑stage venture funds: aim for $100‑$200 million in assets under management to maximize impact and returns. The speaker traces early seed funds—65, 145, 195—and argues that today it’s difficult to raise less...

Citrini Research Breakdown: Agents, "Ghost GDP", Consumer Spend | Figma Earnings Beat
The 20VC episode dissected the disruptive potential of AI agents, highlighting Anthropic's new security product that erased billions in SaaS market capitalizations and a secondary sale that created hundreds of decamillionaires. Hosts argued that agents could reduce incumbent SaaS platforms...

China's Innovative Renaissance: Global Ambitions, New Momentum | Asia Summit 2025
China is transitioning from a manufacturing hub to a global innovation engine, with AI‑native startups, electric‑vehicle giants, and consumer brands eyeing overseas markets. State‑backed policies and a new generation of entrepreneurs embed international ambition into corporate DNA. The panel at...

Techstars: The Best Accelerator for Founders (Here's Why)
The video promotes Techstars as the premier accelerator for early‑stage founders, highlighting its three‑month, mentorship‑driven program that promises lifelong access to a global network of mentors, investors, and corporate partners. Key data points include more than 10,000 founders who have joined,...

Sub-Q Bionics Company Showcase | MedTech World Middle East 2026
At MedTech World Middle East 2026, Sub‑Q Bionics CEO Jordan Pollack unveiled a “bionic lymph node,” an implantable microporous device with an integrated pump that continuously drains excess lymphatic fluid. The system syncs to a cloud‑based platform that applies AI...